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Abstract: We previously identified an extracellular matrix (ECM) gene expression pattern in breast
cancer (BC), called ECM3, characterized by a high expression of genes encoding structural ECM
proteins. Since ECM is reportedly implicated in response to therapy of BCs, the aim of this work is to
investigate the prognostic and predictive value of ECM3 molecular classification in HER2-positive
BCs. ECM3 resulted in a robust cluster that identified a subset of 25–37% of HER2-positive tumors
with molecular aggressive features. ECM3 was significantly associated with worse prognosis in two
datasets of HER2-positive BCs untreated with adjuvant therapy. Analyses carried out on two of
our cohorts of patients treated or not with adjuvant trastuzumab showed association of ECM3 with
worse prognosis only in patients not treated with trastuzumab. Moreover, investigating a dataset that
includes gene profile data of tumors treated with neoadjuvant trastuzumab plus chemotherapy or
chemotherapy alone, ECM3 was associated with increased pathological complete response if treated
with trastuzumab. In the in vivo experiments, increased diffusion and trastuzumab activity were
found in tumors derived from injection of HER2-positive cells with Matrigel that creates an ECM-rich
tumor environment. Taken together, these results indicate that HER2-positive BCs classified as ECM3
have an aggressive phenotype but they are sensitive to trastuzumab treatment.
Keywords: extracellular matrix; HER2 positive breast cancer; gene expression; ECM3; collagen; trastuzumab
1. Introduction
The extracellular matrix (ECM) of a tumor is composed of a complex mixture of proteins that,
other than providing structural support to cells and tissues, influences tumor progression and response
to therapy [1,2]. Differences in ECM-associated gene expression are able to describe the biological and
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clinical heterogeneity of breast cancer (BC). At Fondazione IRCCS Istituto Nazionale dei Tumori (INT),
we identified an extracellular matrix gene expression pattern (ECM3) in ~40% of BCs that is able to
classify a group of tumors independent of their molecular intrinsic subtype and is associated with
poor prognosis in patients with undifferentiated grade III tumors [3,4]. These tumors are characterized
by overexpression of a robust cluster of genes mainly encoding structural ECM proteins and by
overexpression of pathways related to epithelial to mesenchymal transition (EMT). The induction of
EMT in tumor cells is driven by the interplay between myeloid-derived suppressor cells (MDSCs) and
the ECM [5].
Breast cancer is the most frequent female type of cancer and the leading cause of cancer-related
mortality worldwide. The American Cancer Society estimated 250,000 new BC cases and ~40,000
deaths from this disease in 2019 [6]. The HER2 gene is amplified and/or overexpressed in approximately
20% of BCs [7], and has been associated with tumor progression and poor prognosis [8]. Trastuzumab,
a recombinant humanized monoclonal antibody that binds to the extracellular domain of HER2, has
changed the natural history of these tumors, improving patient survival [9]. However, this antibody,
administered per currently approved protocols, is effective in ~50% of patients with this type of
tumor. No predictive biomarkers are clinically available [10], even if pathological and molecular
characterization of tumor tissues has identified tumor-intrinsic features (ER, PAM50 and TRAR) [10–12]
and immune features [13] as predictive of trastuzumab efficacy.
Since ECM is reportedly implicated in response to therapy of BCs [14] and ECM3 contained
35–40% of HER2-positive BCs [4], herein, we tested the prognostic and predictive value of ECM3
molecular classification in HER2-positive BCs.
2. Materials and Methods
2.1. Patients
The 44 tumors of the FIRB cohort were obtained from BC patients treated with
adjuvant chemotherapy between 1981 and 2002, after selection based on HER2 positivity by
immunohistochemistry (IHC) (3+ or 2+) and fluorescence in situ hybridization (FISH) (only tested in
IHC 2+) as potential targets of trastuzumab treatment. All selected samples contained at least 70%
tumor cells.
All procedures were in accordance with the Helsinki Declaration. Biospecimens used for research
consisted of leftover material of samples collected during standard surgical and medical approaches at
INT. Samples were donated by patients to the Institutional BioBank for research purposes, and aliquots
were allocated to this study after approval by the Institutional Review Board and a specific request to
the Independent Ethical Committee of the institute.
2.2. Immunohistochemistry and Fluorescence In Situ Hybridization
HER2, ER and PGR positivity of cases of the FIRB cohort were re-evaluated (HER2:
A0485; ER: clone 1D5, M7047; PGR: clone PgR636, M3569, Dako, Santa Clara, CA, USA) on
formalin-fixed, paraffin-embedded (FFPE) tissue sections. The immunoreaction was developed using
the streptavidin–biotin–peroxidase technique, followed by counterstaining with Carazzi hematoxylin.
HER2 positivity was defined as 3+ overexpression in more than 10% of tumor cells by IHC or 2+
overexpression and HER2 amplification ratio of at least 2.2 by FISH. Tumors were considered ER- or
PGR-positive if at least 10% of cells showed immunoreactivity.
All HER2 2+ cases were evaluated by FISH using the PathVysion HER-2DNA Probe kit (Abbott,
Chicago, IL, USA) according to the manufacturer’s recommendations, as previously described [15].
Briefly, 2 µm FFPE sections were deparaffined in Hybrite (Abbott) and rehydrated. After pepsin
treatment (0.01 N HCl + 0.4% pepsin) at 37 ◦C for 6 min, samples were denatured at 85 ◦C for 1 min and
hybridized with probes overnight at 37 ◦C. Samples were stained with 4′,6-diamidino-2-phenylindole,
cover-slipped and analyzed with a Zeiss Axioscop 2 microscope (Carl Zeiss, Oberkochen, Germany).
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2.3. RNA Isolation and cDNA Microarray Techniques
Total RNA was extracted from snap-frozen samples using Trizol (Thermo Fisher Scientific, Waltham,
MA, USA) following the manufacturer’s instructions. Integrity of the RNA was assessed by agarose gel
electrophoresis after DNase I and clean-up treatment with RNeasy mini kit (Qiagen, Hilden, Germany).
All processed tumor specimens contained at least 70% cancer cells. A radiolabeled tracer was added
during the cDNA synthesis and a small amount of the cDNA was run on an alkaline gel (1% agarose,
50 mM NaOH, 1 mM EDTA). Only cDNAs showing a similar core size of 1–1.5 k nucleotides were used
for subsequent hybridization. The target cDNAs were synthesized from total RNA and directly labeled
with Cy3-dCTP (reference RNA) or Cy5-dCTP (sample RNA) (GE Healthcare, Buckinghamshire, UK) and
indirectly with 3DNA Submicro Expression Array Detection kit (Genisphere, Hatfield, PA, USA). Total
RNA was reverse transcribed using 5′ end modified oligo-dT primers containing the specific Cy3 or Cy5
3DNA capture sequences. The 32P-labeled cDNAs with an estimated activity of about 100,000 counts per
minute were annealed with 1.5 µL of the specific DNA capture reagent for 16 h at 41 ◦C. Hybridization
was carried out in a hybridization station (Genomic Solutions, Cridersville, GE, USA) and slides were
scanned using the GenePix 4000A microarray scanner (Molecular Devices, Sunnyvale, CA, USA).
2.4. Data Analysis
Dataset filtering and Lowess normalization were performed using J-Express (Molmine, Hafrsfjord,
Norway) as described [16]. Bioinformatic analyses were performed using R [17], version 2.15, and
BioConductor [18], release 2.10. Gene-set enrichment analyses were performed using gene set
enrichment analysis GSEA v5.0 [19]. Genes represented by more than one probe were collapsed to the
probe with the maximum value using the Collapse Dataset tool. Gene-set permutation was applied
1000 times and gene-set enrichment was considered significant at FDR < 25%.
2.5. External Datasets and Signatures
ECM3 was calculated in HER2-positive patients of the following public datasets: NKI (Netherlands
Cancer Institute) (untreated) [20]; ii) EMC (untreated) [21]; GSE50948 (NOAH trial, treated with
neo-adjuvant chemotherapy alone or chemotherapy and trastuzumab) [22]. Microarray data were
analyzed starting from processed data retrieved from GEO. Gene expression data of the GHEA cohort
(GSE55348), containing tumors treated with adjuvant trastuzumab-based therapy in our institute,
were also used [23]. HER2-overexpressing tumors in EMC and NKI datasets were selected based on
mRNA levels of genes in the 17q12 amplicon reported to be overexpressed in HER2-positive tumors, as
described [24]. In detail, cluster analysis was performed with genes belonging to the ERBB2 amplicon
after performing median centering of the amplicon genes using Cluster 3.0 and TreeView softwares.
Tumors in the cluster with overexpression of these genes were considered amplified.
ECM3 was identified using the Large Average Submatricies (LAS) biclustering method [25];
compactness and separation of cluster partitions were evaluated using the Dunn index and silhouette
width [26]; connectedness of clusters was quantified using the connectivity measure [26], as previously
described [4].
The research-based PAM50 subtype predictor was applied to the GHEA and NOAH datasets using
the publicly available algorithm as described [22], after performing median centering of the PAM50
genes. Immune metagenes were determined based on the method of Rody et al. [27]. The average
log-transformed expression of the genes that belonged to each metagene was calculated.
2.6. In Vivo Study
Experimental protocols were approved by the Ethics Committee for Animal Experimentation of
Fondazione IRCCS-INT. Care and use of the animals were in accordance with institutional guidelines.
Six- to eight-week-old CD1 athymic female mice were purchased from Charles River. Mice (4/group),
housed 4 per cage (1 cage for group) with food and water available ad libitum, were injected
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subcutaneously with 1 × 106 SKOV3 cells in PBS. HER2-positive SKOV3 cells purchased from the
American Type Culture Collection (ATCC) were cultured in RPMI 1610 medium (Euroclone, Pero,
Italy) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific) in a humidified
chamber (95% air, 5% CO2) at 37 ◦C. Cells were authenticated using the Short Tandem Repeat Profiling
method in our institute’s facility. To generate an extracellular matrix-rich model, cells were embedded
in 100 µL of Matrigel and injected in athymic mice. To assess trastuzumab-mediated therapeutic effects,
trastuzumab was administered 4 mg/kg i.p. twice a week starting one week after cell injection. Tumors
were calibrated once a week and tumor volume was calculated as 0.5 × d12 × d2, where d1 and d2 are
the smaller and largest diameters, respectively.
To quantify the amount of trastuzumab that reached the tumor tissue, mice bearing 0.2 cm3
tumors were treated with 10 mg/kg 131I-Trastuzumab and analyzed for antibody radiolocalization 48 h
after drug injection. Radiolabeling was carried out using the Chizzonite method for indirect protein
iodination with IODO-GEN® pre-coated tubes following the manufacturer’s instructions (Thermo
Fisher Scientific). The obtained radiolabeled antibody was diluted with saline solution to a final
concentration of ~6 MBq/mL and injected at 1.3–1.5 MBq/0.25 mL/mouse. Radioactivity was quantified
in tumors and in muscle as reference with COBRA II Auto-Gamma counter (Packard, PerkinElmer,
Waltham, MA, USA).
Trastuzumab was also quantified 24 h after injection by immunofluorescence. Tumors were
removed, fixed in 4% paraformaldehyde and OCT, frozen in liquid nitrogen, sectioned (5-µm), and
processed for immunofluorescence (IF) labeling. Slides were saturated with 3% BSA and incubated
with mouse Ab anti-mouse collagen I-III (NB600-450 and NB600-451, Novus Biologicals, Centennial,
CO, USA) and incubated with a specific Alexafluor-conjugated (Thermo Fisher Scientific) secondary
antibody. Trastuzumab was visualized using Alexafluor-conjugated anti human secondary antibody.
Nuclei were visualized by Sybr-green. Coverslips were mounted on glass slides using Prolong
(Calbiochem, San Diego, CA, USA) and examined with a confocal microscope (Microradiance 2000,
BioRad, Hercules, CA, USA) equipped with Argon (488 nm), Green HeNe (543 nm) and Red diode
(633 nm) lasers. Images were obtained using a ×60 oil immersion lens (512 × 512 or 1024 × 1024 pixels)
and analyzed using Image-Pro Plus v. 7.0.1 (MediaCybenetics, Rockville, MD, USA) software.
2.7. Statistical Analysis
Relationships between categorical variables were assessed using Fisher’s exact test. Two-tailed
Student’s t-test was used to compare mean values of two independent groups.
Disease-free survival (DFS) was defined as the time elapsed from the date of surgery to the date
of the first event. Overall survival (OS) was defined as the time elapsed from the date of surgery
to the date of death from any cause or the date of last follow-up. Kaplan–Meier survival plots and
exact log-rank tests were used to assess differences in DFS and OS between two groups. Adjusted
hazard ratios (HRs) of prognostic factors together with 95% confidence intervals (CIs) were estimated
by fitting multivariable Cox survival models. All the analyses were conducted using SAS software
(SAS Institute Inc., Cary, NC, USA). Two-sided p-values < 0.05 were considered statistically significant.
3. Results
3.1. Identification of ECM3 HER2-Positive Breast Carcinomas
To test the relevance of our previously described signature ECM3 [4] in HER2-positive BCs,
we studied the expression profile of ECM-related genes by LAS method in 5 cohorts of primary
HER2-positive BCs. As already described for consecutive BCs, ECM3 was detectable in every dataset
analyzed. In total, 25% to 37% of the cases were classified as ECM3 (Table 1). The average silhouette of
ECM3 clusters in the 5 datasets ranged from 0.21 to 0.34, the Dunn indices ranged from 0.45 to 0.59
and connectivity ranged from 5.4 to 12.4, indicating a highly significant partition of ECM3 subset also
among HER2-positive BCs.
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Contrary to what we previously observed in BC cohorts containing tumors of all intrinsic
subtypes [4], in which ECM3 tumors were mainly ER positive and grade I-II, ECM3 was not significantly
associated with any clinico-pathological variable in all the datasets analyzed (Table 1).
To explore the possibility of providing biologically meaningful insights to this classification in
HER2-positive tumors, we used GSEA. Comparison of gene expression in ECM3 vs. non-ECM3 tumors
revealed significant enrichment for pathways we previously found associated with ECM3, such as
EMT, cell and focal adhesion, TGF-beta pathway, tumor metastasis and hypoxia (Figure 1), confirming
the biological characteristics of ECM3 tumors also among HER2-positive tumors. Genes related
to inflammation were found enriched in non-ECM3 tumors (Figure 1), as previously observed [4].
Nevertheless, this enrichment was not observed in all analyzed datasets.
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Figure 1. Molecular characteristics of HER2-positive breast cancers (BCs) according to ECM classification.
Heatmap shows the normalized enrichment scores (NES) of gene sets significantly enriched at FDR < 25%
in ECM3 tumors in at least two datasets, by GSEA analysis. Grey boxes indicated no enrichment.
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Table 1. Frequency of clinico-pathological characteristics of patients according to the extracellular matrix gene expression pattern (ECM3).
EMC 29% NKI 25% FIRB 34% GHEA 31% NOAH 37%
Variable
ECM3 Non-ECM3 ECM3 Non-ECM3 ECM3 Non-ECM3 ECM3 Non-ECM3 ECM3 Non-ECM3
(n = 14) (n = 35) (n = 13) (n = 39) (n = 15) (n = 29) (n = 11) (n = 25) (n = 42) (n = 72)
Estrogen receptor
Positive 9 (64%) 24 (69%) 8 (62%) 25 (64%) 5 (33%) 16 (55%) 6 (55%) 12 (48%) 11 (26%) 16 (22%)
Tumor size
>T1 NA NA 7 (54%) 20 (51%) 13 (93%) 23 (79%) 5 (45%) 12 (48%) NA NA
Histological grade
III NA NA 6 (46%) 24 (62%) 9 (69%) 19 (68%) 8 (73%) 20 (80%) 21 (50%) 40 (56%)
Lymph node status
Positive 0 0 8 (62%) 18 (46%) 10 (71%) 19 (66%) 10 (91%) 21 (84%) NA NA
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3.2. ECM3 in HER2-Positive BCs Not Treated with Trastuzumab
To test the prognostic significance of ECM classification in HER2-positive tumors the performance
of ECM3 was investigated in 49 and 52 untreated HER2-positive tumors from EMC and NKI datasets,
respectively. Univariate analysis indicated worse DFS for ECM3 tumors in both datasets (Figure 2 and
Table S1). Moreover, ECM3 resulted an independent prognostic factor of worse DFS in multivariate
analysis with estrogen receptor (ER) in both datasets (HR = 5.50, 95% CI = 2.07–14.6 and HR = 2.57,
95% CI = 1.06–6.19, respectively) (Table 2). ECM3 remained the variable most associated with DFS
probability in the NKI dataset in multivariate analysis with other available clinico-pathological variables
(Tables S1 and S2). OS in NKI patients with ECM3 tumors was also significantly worse (Table S3).
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Figure 2. ECM3 prognostic significance in HER2-positive BC patients. (a,b) Association between
ECM3 (red line) and non-ECM3 (black line) and disease-free survival (DFS) in untreated HER2-positive
BC patients of the EMC (a, n = 49) and NKI (b, n = 52) datasets. (c) Association between ECM3 and
non-ECM3 and DFS in HER2-positive BC patients (FIRB cohort) treated with adjuvant chemotherapy
witho t trastuzumab. p-values by log-rank test.
Table 2. Multivariate proportional hazard analyses of DFS.
EMC NKI FIRB
Variable HR (95%CI) p-Value HR (95%CI) p-Value HR (95%CI) p-Value
ECM3 5.50 (2.07–14.62) 0.0006 2.57 (1.06–6.19) 0.0361 2.29 (0.76–6.87) 0.1383
ER pos 0.58 (0.22–1.54) 0.2730 0.46 (0.20–1.09) 0.0781 1.09 (0.36–3.29) 0.8800
We n xt valuated prognosis of patients w th ECM3 tumors treated with adjuvant c emotherapy.
A total f 44 HER2-positive cases (35 amples 3+ and 9 samples 2+/FISH positive) treated with
chemotherapy in our institute before the introduction of trastuzumab in the clinical practice were
selected. The Kaplan–Meier curve showed a worse prognosis for patients with ECM3 tumors (p = 0.0494,
Figure 2). ECM3 was the variable more associated with DFS and OS both in univariate (Table S1) and
multivariate analyses (Table 2 and Table S3), indicating that ECM3 cases have a worse prognosis even
if treated with chemotherapy.
3.3. ECM3 in HER2-Positive BC Treated with Trastuzumab
To understand whether ECM3 cases could benefit from trastuzumab treatment, we analyzed the
ECM signature in a cohort of patients treated in our institute with adjuvant trastuzumab-based therapy.
Cases of the GHEA cohort [23] were submitted to LAS biclustering to identify ECM3 tumors. ECM3 was
not associated with any clinico-pathological variables (Table 1) and it was not found associated with
worse prognosis in these cases, but a trend toward better prognosis was observed (Figure 3), suggesting
that ECM3 cases could benefit from trastuzumab treatment. We also investigated whether ECM3 was
associated with other predictors of trastuzumab benefit, like PAM50 [22] and TRAR, that were previously
developed in the GHEA datasets [23]. No association was found between ECM3 and HER2-enriched or
TRAR-low, the two subsets of cases who best benefit from trastuzumab treatment (Figure S1).
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pCR (48%, p = 0.0560). Non-ECM3 cases respond well both to chemotherapy (42% of pCR) and
trastuzumab (50% of pCR, p = 0.0948, Figure 3). To more deeply investigate the association between
ECM3 and immune signatures in relation to pCR, we calculated the value of the immune metagenes
described to be associated with pCR in this dataset [28]. Hemopoietic cell kinase (HCK) metagene
and MHC-II metagene, surrogate markers of cells belonging to the monocyte/myeloid lineage and
of antigen-presenting cells, respectively, were found to be significantly higher expressed in ECM3
tumors (p < 0.001), but not associated with response either in cases of the chemotherapy arm or in
those receiving trastuzumab (Figure S2). On the contrary, lymphocyte specific kinase (LCK) and STAT1
metagenes were found significantly more expressed in ECM3 tumors of patients who achiev d pCR vs.
residual disease (RD) only if treated with trastuzumab (Figure S2), uggesting a possible combination
of these markers to improve prediction of trastuzumab benefit.
3.4. Extracellular Matrix and Response to Trastuzumab in a Xenograft Model
To test whether the presence of high amounts of ext acellular matrix overexpr ssed in ECM3
tumors could impact trastuzumab diffusion and antitumor activity, the HER2-amplified carcinoma cell
line SKOV3 was injected in nude mice with or without Matrigel and then treated with trastuzumab
(Figure 4a). No sign of toxicity by treatment was observed (Figure S3). While the presence of Matrigel
increased the growth rate of these xenografts, trastuzumab-mediated reduction of tumor growth was
significantly greater in tumors grown in ECM-rich tumors compared with those grown in the absence
of ECM (Figure 4b). Ki67 immunoreactivity of tumor tissues collected at the end of the treatment was
not reduced by trastuzumab both in tumors containing or not containing Matrigel (data not shown).
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Figure 4. Role of extracellular matrix density in trastuzumab efficacy. (a) Scheme of the in vivo
experiments. (b) Tumor volume and percent tumor growth inhibition by trastuzumab at day 42 in
tumors obtained from injection of cells with (+ Matrigel) or without (−Matrigel) Matrigel. Data are
mean ± SD (n = 4). (c) 131I-Trastuzumab quantification in tumors obtained from injection of cells in
mice with (+ Matrigel) or without (−Matrigel) Matrigel 48 h after treatment with 131I-Trastuzumab.
Data are mean ± SD of the ratio between radioactivity (count per minute) quantified in the tumor
and in the muscle of the same mouse (n = 5). (d) Representative images of trastuzumab localization
evaluated by immunofluorescence in tumors of mice injected with cells embedded (+) or not (−) in
Matrigel (red: trastuzumab, green: sybr green, nuclei, blue: collagen). (e) Trastuzumab quantification
in tumors grown with (+) or without (−) Matrigel 24 h after treatment. Data are mean ± SD (n = 4)
of the mean fluorescence intensities of red positive pixels normalized on the number of green pixels
(nuclei). p-values by unpaired t-test.
By using labelled 131I-trastuzumab, we investigated if the presence of atrigel could have
influenced drug accumulation within the tumors. As shown in Figure 4c, a major amount of trastuzumab
was quantified in tumors grown i the presence of Matrigel. Moreover, confocal microscopy a alysis
confirmed higher uptake f trastuzumab in Matrigel-mixed tumors th n n tu ors derived without
Matrigel (Figure 4d,e), supportin the notion that increased drug delivery and efficacy is associated
with collagen accumulation. These d ta suggested a clear influence of the cross-talk between tumor
and ECM on trastuzumab efficacy.
4. Discu sion
ECM3 is one group of BCs previously identified ac ording to t i f genes [3],
that is characterized by overexpression of a peculiar pattern of genes ai l e c i structural
ECM molecules [4]. Our present analysis in cohorts of ER2-positive tumors identified ECM3 as
a stable tumor partition also within this intrinsic subtype of BCs. Moreover, biological features of
this subset of tumors are concordant with what we have previously described. Indeed, pathways
related to EMT, hypoxia, tumor metastasis, TGFβ signaling pathway and adhesion to the matrix are
enriched in these tumors, all features associated with tumor aggressiveness [29] that can explain the
poor prognosis of patients with ECM3 tumors. Moreover, pathways related to stem cells (i.e., Wnt,
Hedgehog pathways [30]) were found enriched in these tumors. This is in line with a described
increase in stem cell markers when cells are exposed to collagen [31], and with the ability of BC cells
with stem-like phenotypes to express an increased level of collagens [32].
ECM3 tumors were found associated with poor prognosis if untreated or treated with chemotherapy
alone. It is likely that tumor microenvironment organization in ECM3 tumors contributes to resistance
to chemotherapy. Several studies have shown that tumor microenvironment can contribute to resistance
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to chemotherapeutic agents through different mechanisms [2]. Resistance was described to be mainly
associated with pro-survival signals derived from interaction between tumor cells and the matrix, or
by the organization of the ECM that can limit blood flow and thus restrict diffusion of the drug into
the tumor [33,34]. In this context, some genes belonging to the ECM3 pattern were described to be
associated with resistance to tamoxifen in metastatic ER-positive BCs [35] and to FEC chemotherapy in
neoadjuvant treated ER-negative BCs [36]. Moreover, in the HER2 subtype high SPARC expression,
one of the leading genes of ECM3, other than being associated with poor prognosis, was found
associated with low pCR rates in patients treated with anthracyclines and taxanes [37]. Furthermore,
EMT and stem-like features, enriched in ECM3 tumors, have been largely associated with resistance
to chemotherapy [38]. Thus, combination therapy targeting tumor and stromal characteristics also
exploiting new approaches for drug delivery [39,40] could represent a new strategy to improve
chemotherapy response in ECM3 tumors and requires further investigation.
Treatment with trastuzumab improves the prognosis of ECM3 patients and significantly increases
the percentage of pCR. The high infiltration of ECM3 tumors by CD8+ T cells, described in a preclinical
model to be relevant for trastuzumab activity [13] and that we previously found associated with
trastuzumab benefit also in clinical samples [23], could be at the basis of the response. The presence of
CD8+ cells in the ECM3 tumor microenvironment is in contrast with the poor prognosis of patients with
this type of tumor, but the presence of immunosuppressive cells, like MDSC, described to be enriched
in contact with tumor cells in ECM3 tumors [5], could suppress their antitumor activity. The association
between ECM3 and immune metagenes in the NOAH dataset further supports an altered host response
in ECM3 tumors, as observed in collagen-dense tumors [41]. The altered infiltration of immune
cells in these tumors could be at the basis of trastuzumab efficacy. Higher expression of the T-cell
surrogate LCK metagene and STAT1 metagene in ECM3 vs. non-ECM3 tumors who achieve pCR
further supports this hypothesis.
Another possible explanation of the benefit of ECM3 tumors from trastuzumab derived from
their stem cell-like features. Indeed, breast cancer stem cells rely on HER2 and are sensitive to
trastuzumab [42]. In addition, the tumor microenvironment architecture derived from the production
of ECM3 proteins could influence diffusion and accumulation of the drug in the tumor tissue as
we found in Matrigel-mixed tumors in mice. These data seem to be in contrast with many studies
illustrating the relevance of ECM density and composition in the ability of drugs to distribute and
accumulate in the extravascular compartment of the tumor tissue [43]. However, trastuzumab has
been shown to have a relatively high interstitial volume of distribution in solid tumor models due to
its positive charge [44].
We are aware that the use of Matrigel to create an ECM-rich environment is not a perfect model
of the ECM3 microenvironment, but our previous findings using this model, showing resistance to
doxorubicin and low penetration of the drug in the tumor microenvironment [45], as observed in
patients with ECM3 tumors, support our results. It cannot be excluded that the higher concentration of
trastuzumab in these tumors derived from a different organization of the tumor microenvironment,
characterized by a small nest of tumor cells separated by area of ECM, opposed to the tumor cell
packed tumors derived from injection of tumor cells alone. The lack of Ki67 reduction by trastuzumab
in xenografts is in line with data obtained in the MMTV/HER2 model [46] and in HER2-positive locally
advanced BCs from patients treated with neoadjuvant trastuzumab [47], in which Ki67 is not modified
by trastuzumab treatment. It is conceivable that tumor cell proliferation is inhibited by trastuzumab
therapy, as observed in other models a few days after the start of the treatment [48,49]. Thus, it is likely
that a reduction in proliferation rate occurs mainly at the beginning of the treatment, as suggested also
by a strong reduction in Ki67 positivity in tumor tissue of HER2-positive BC patients of a window of
opportunity trial treated with one cycle of trastuzumab [50].
The small number of patients and the heterogeneous group of tumors constitute the major
limitation of the study. Further analysis of the predictive value of ECM3 is warranted. Moreover,
from a clinical point of view, understanding whether the addition of ECM3 to the immune signatures
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increases the selection of patients who benefit from trastuzumab could represent an important issue
for patient selection in the clinical practice.
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